(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/211990 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *C07D 491/04* (2006.01)
C07D 403/04 (2006.01) *A61P 25/00* (2006.01)
C07D 471/04 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/US2023/019879

(22) International Filing Date:
25 April 2023 (25.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202211024240 25 April 2022 (25.04.2022) IN
202311013223 27 February 2023 (27.02.2023) IN

(71) Applicant: **SITEONE THERAPEUTICS, INC.** [US/US]; 280 Utah Avenue, Suite 250, South San Francisco, California 94080 (US).

(72) Inventors; and

(71) Applicants: **ZHU, Jie**; c/o SiteOne Therapeutics, Inc., 280 Utah Avenue, Suite 250, South San Francisco, California 94080 (US). **MULCAHY, John**; c/o SiteOne Therapeutics, Inc., 280 Utah Avenue, Suite 250, South San Francisco, California 94080 (US). **PRAKASH, Hari**; c/o Jubilant Biosys Limited, B-34 Sector 58, Noida, Uttar Pradesh 201301 (IN). **UPADHYAY, Puspesh Kumar**; c/o Jubilant Biosys Limited, B-34 Sector 58, Noida, Uttar Pradesh 201301 (IN).

(74) Agent: **ADAMS, Michael J.** et al.; 475 Sansome Street, Suite 1600, San Francisco, California 94111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA $_V$1.8 FOR THE TREATMENT OF PAIN

FIG. 1



Figure 1. Voltage protocols for Nav test procedure (Protocol A)



(I)

(57) Abstract: Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 1-206. (Formula (I))

[Continued on next page]

WO 2023/211990 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*